Mpm Asset Management adds Syndax Pharmaceuticals Inc (SNDX) to its portfolio

Syndax Pharmaceuticals Inc (SNDX) : Mpm Asset Management added new position in Syndax Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 2,168,691 shares of Syndax Pharmaceuticals Inc which is valued at $27.7 Million , the company said in a statement filed on May 11, 2016 with the SEC.Syndax Pharmaceuticals Inc makes up approximately 9.96% of Mpm Asset Management’s portfolio.

Other Hedge Funds, Including , Catalyst Capital Advisors added SNDX to its portfolio by purchasing 182 company shares during the most recent quarter which is valued at $2,321. Blackrock Investment Management added SNDX to its portfolio by purchasing 18,086 company shares during the most recent quarter which is valued at $230,597. Blackrock Advisors added SNDX to its portfolio by purchasing 308,693 company shares during the most recent quarter which is valued at $3.9 Million. Jennison Associates added SNDX to its portfolio by purchasing 460,892 company shares during the most recent quarter which is valued at $6.7 Million. Syndax Pharmaceuticals Inc makes up approx 0.01% of Jennison Associates’s portfolio. Kornitzer Capital Management Inc Ks added SNDX to its portfolio by purchasing 40,000 company shares during the most recent quarter which is valued at $579,600. Syndax Pharmaceuticals Inc makes up approx 0.01% of Kornitzer Capital Management Inc Ks’s portfolio.

Many Wall Street Analysts have commented on Syndax Pharmaceuticals Inc. Morgan Stanley Initiated Syndax Pharmaceuticals Inc on Mar 28, 2016 to “Overweight”, Price Target of the shares are set at $22.Citigroup Initiated Syndax Pharmaceuticals Inc on Mar 28, 2016 to “Buy”, Price Target of the shares are set at $24.JMP Securities Initiated Syndax Pharmaceuticals Inc on Mar 28, 2016 to “Mkt Outperform”, Price Target of the shares are set at $28.

Syndax Pharmaceuticals Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of entinostat as a combination therapy in multiple cancer indications with a focus on tumors that are sensitive to immunotherapy including lung cancer melanoma ovarian cancer and triple-negative breast cancer (TNBC). The Company is also developing Entinostat as a combination therapeutic in a Phase III clinical trial which is being conducted with ECOG-ACRIN for advanced hormone receptor positive (HR+) breast cancer. The Company’s Entinostat is an oral small molecule histone deacetylase (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells and also enhances the body’s immune response to tumors. The Company’s product pipeline for immune-oncology includes ENCORE 601 ENCORE 602 ENCORE 603 J1353 NCI-7870 and NCI-9844. Its pipeline for advanced HR+ breast cancer includes E2112.

Leave a Reply

Syndax Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Syndax Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.